The Manager
Corporate Relationship Department
BSE Limited
Floor 25, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code - 530199

The Manager - Listing Department National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (East), Mumbai- 400051
Symbol: THEMISMED

Dear Sir/Madam,

## Sub: $\quad$ Newspaper Advertisement pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

In terms of Regulations 47 of the SEBI Listing Regulations, the Company has published the extract of Un-Audited Standalone and Consolidated Financial Results for the Quarter ended 31st December, 2023 in the 'Indian Express' (English) edition and in 'Financials Express' (Gujarati) edition on Monday, 12 ${ }^{\text {th }}$ February, 2024.

Further, in pursuance of Regulation 30 read with Schedule III (A)(12) of the SEBI Listing Regulations, please find enclosed the copy of Newspaper articles as published in the abovementioned newspapers.

Kindly take the same on record and acknowledge receipt.

Thanking you,
Yours Faithfully,
For Themis Medicare Limited,

```
SANGAMESHWA Digitally signed by
R RAMNARAYAN ramNARAYAN IYER
YER Date: 2024.02.12 13:04:49
```

Sangameshwar lyer
Company Secretary \& Compliance Officer

Encl: a/a

## Themis Medicare Limited

Corporate Office: 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai - 400 104, India
*Tel.: 91-22-67607080*Fax: 91-22-67607070/ 28746621
Regd. Office: Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat
CIN No.: L24110GJ1969PLC001590 *Tel/ Fax No.: Regd. Off.: 0260-2431447/ 2430219
*E-mail: themis@themismedicare.com*Website: www.themismedicare.com



 4They're used for
rusted bearing (7) Acommunication yourin
inderstand when you geti ${ }_{8}{ }_{8}$ rustedt trunnering down $(7)$ mountains (3) Resare contro to te 9 Temppe tooeaboorate as a clan


 Hind hanioa 6 Common pride in some Gothic
architecture (3) ${ }_{1} 13 \mathrm{Number}$ fereigious work 15 Numberafter a ne
bomm explosive (6)
18 Creep around ina 1ubler sole accomp
her lightweight( $)$ 21 Barele coountenancee
23 A cot's surprised ${ }^{23 \text { Ascot's surpri }}$
$\qquad$


## JUMBLED WORDS




## SALUTE THE SOLDIER



Our salutation to a brave and motivated soldier
who made supreme sacrifice on 12 feb 2019 while who made supreme sacrifice ond motivated soldier 2019 while
fighting with tourist in an encounter at Ratanpur,
Pullwama JATS proudly remember him and his supreme of us and the paltan is proud of you.
Colonel Bhisham Chauhan and all Ranks

## WESTIERNBAILWAYEAHMEDABAD DIVISION       

 WESTIERN RAILWAY-VADODARA DIVISION E-AUCTION FOR THE CONTRACTS OF "PAY \& USE" CONTRACT -Auction for the contracts of "Pay \& Use", Contract. will be held on9.02.2024. The e-auction will start at 10.00 hrs on 19.02 . 2024 T catalogue has already been published on www.ireps.gov.in website. | Catalogue |
| :---: | :---: |
| No. | \(\begin{gathered}Type of <br>

Contract\end{gathered}\)

"IMPORTANT" acceptance of advertising copy, itis not possible toverify
its contents. The Indian Express ( $(P)$ Limited cannot
be held responsible forsuch be held responsible for such
contents, nor for any contents, nor for any losss transactions with companies,
associations or individual associations or individuals
advertising in its newspapers or Publications. We therefore recommend that readers
make necessary inquir before sending any monies or entering into any
agreements with advertisers or otherwise acting on an advertisement in
manner whatsoever.




## આઈનોક્સ વિન્ડ આગામી થોડા ત્રિમાસિક ગાળામાં અનુકૂળ બજાર પર નફો નોંધાવશો

પીટીઆઈ
નવી દિલ્હી, તા. ૧૧
વિન્ડ એનર્જી સોલ્યુશન
પ્રોવાઇડર આઇનોક્સ વિન્ડ
ડિસેમ્બર ૨૦૨૩ના ત્રિમાસિક
ગાળામાં તેનો
વ્યવસાય ફરી વળ्યા બાદ
તેની વૃદ્ધનનો માર્ગ ચાલુ રાખે

ઓર્રૂ બુક અને ઊંચી આવકથી પ્રેરિત છે, એમ એેક ટોયના ગાળામાં તેના કર પછીના નફા


 તેની વૃદ્ધિનો માર્ગ ચાલુ રાખે

 કમમકક્સ અને રિન્યએેબલ સ્પેસમાં કામ કરે છે. શ્લુક્વારે, આઇનોક્સ વિન્ડે


 सスકારનં લષ્ષ सરકારું લક્ષ આગામી વાણિ|જ્યિક અને ઔદોગાક ઘાયકામાં પવનની ક્ષમમામાં (સીએન્ડઆઇ) ગ્રાહકો જેવા

આગામી
 સાદા વिन्ड ટેન્ડર અને

 ડિસ્પેચેબલ એનર્જી આ્વોનોક્સ વિન્ડ માટે નોંધપાત્ર ોજેક્ટસ શર ક્વાપાં

## c <br> glenmark <br> LIFE SCIENCES

GLENMARK LIFE SCIENCES LIMITED

| Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur - 413 213, India. Corporate Office: 4 ${ }^{\text {th }}$ Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai-400 099, India. Phone No.: +91 22 68297979; Website: www.glenmarklifesciences.com; Email: complianceofficer@glenmarklifesciences.com |  |  |
| :---: | :---: | :---: |
| Recommendation of the Independent Director Committee " "IDC") of Glenmark Life Sciences Limited "TTarget Company" or "TC" in relation to the open offer "Open Offer") made by Nirma Limited ""Acauire") to the Public Sharenolders of the Target Company("Sharenolders") under Regulations $26(7)$ of SEBI (Substantial Accuisition of Shares and Takeovers) Regulations, 2011 and Subsequent Amendments thereto ("SEBl (SAST) Regulations, 2011"). |  |  |
| 1 | Date | 10 Februar, 2024 |
| 2 | Name of the TC | Glenmark Life Sciences Limited |
| 3 | Details of the Offer pertaining to TC |  |
| 4 | Name of the acquirer | Nima Limited |
|  |  | ert(PACS) with the Acquire |
|  | Name of the offer | One BKC, Tower C |

Mumbi - 400051, Maharashtra, India
E-mail: Is of.openoffer@dancapita
Website wumdamcarital in
SEBI Registration No.: MB/INM000011336
Members of the Committe
of In Inependent Directors
Please indicate the
Oindependen Corectors
(Please indicate the
chairperson of the
Com mittee separately)

Director, Equity shares
owned, any other contraa
Mrs. Maniu Agarwal (Member)
Mr. Taruvai Laxninarayyanan Easwar (Member)
Ms. Gita Nayyar (Member)

## of the Target Company

## Company.

Trading in the Equity sharessother securrities of
the TC by 1 IC Members

Al Members of the IDC are Independent Directors of the Target Company.

$$
\begin{aligned}
& \text { Members of the IDC are Independent Directors of the larget Company. } \\
& \text { Mrs. Manju Agarwal, Independent Director and a member of the IDC holds } 1000 \text { equity shares } \\
& \text { of the Target Company. }
\end{aligned}
$$

None of the Members of the IDC hold any other contractual or any other relationship with the
Target Company other than their position as Independent Director of the Target Company.
Mrs. Manju Agarwal, Independent Director and a member of the IDC has purchase 1,000 equity
shares of the Target Company on 28 September 2022.
hares of the Target Company on 28 September, 2022.
None of the other members of the IDC have traded in the Equity Shares/ other securities of Target
Company during the:
a) 12 months prior to the PA Date; and
b) Period from the PA Date and till the date of recommendation.

## None of the members of IDC

## a) are directors on the board of the Acquirer;

b) hold any equity shares or other securties of the Acquirer; or

None of the IDC Members have traded in the Equity Shares/ other securities of Acquirer during the a) 12 months prior to the PA Date; and
b) Period from the PA Date and till the date of recommendation.

The IDC has reviewed the public announcement, detailed public statement and letter of offer
issued by the manager of the offer on behalf of the Acquirer, in connection with the open offer. ssued by the manager of the offer on behalf of the Acquirer, in connection with the open offer. PwC Business Consulting Services LLP which was appointed by the IDC to provide its independen
opinion with respect to the Offer Price, has provided its opinion that: (i) the Offer Price offered by the Acquirer is in accordance with the Regulation 8 (2) of SEBI SAST Regulations; and (ii) the Offer
Price is fair and reasonable as on the PADate. Price is fair and reasonable, as on the PA Date.
Based on the above, the IDC is of the opinion that, the Offer Price of INR 631.2 (Indian Rupees
six hundred thirty one and Paise twenty only) per Equity share offered by the Acquirer: (a) is in six hundred thirty one and Paise twenty only) per Equity share offered by the Acquirer: (a) is in
accordance with the regulation prescribed under the SEBI (SAST) Regulations; and (b) the Ope Offer appears to be fair and reasonable, as on the PA Date.
However, IDC would like to draw attention of the shareholders that post the public announcement
dated 21 September, 2023, the share price of the Company has increased, and the current share pice is higher than the Offer Price.
The shareholders are advised to independently evaluate the open offer and take an informe
ar the the equity shares in the open offer
The IDC has reviewed the public announcement, detailed public statement and letter of offe
issued by the manager of the offer on behalf of the Acquirer, in connection with the open offer. PwC B opinion with respect to the Offfer Price, has provided its opinion that: (i) the Offer Price offered by the Acquirer is in accordance with the Regulation 8 (2) of SEBI SAST Regulations; and (ii) as pe
their report dated 7 February. 2024, the Offer Price of INR 631.2 (Indian Rupees six hundred and heir report dated 7 February, 2024, the Offer Price of INR 631.2 (Indian Rupees six hundred an
hirty one and Paise twenty only) per Equity Share is fair and reasonable, as on the PA Date.
Based on the above, the IDC is of the opinion that, as on the date of this recommendation, the
Offer Price of INR 631.2 (Indian Rupees six hundred thirty one and Paise twenty only) per Equity hare is in compliance with the SEBI (SAST) Regulations and the Open Offer appears to be far and reasonable, as on the PA Date.
However, the members of IDC draw attention of the shareholders to the closing market price o "BSE") ) on on February, 2024, being INR 781.00 Equity Share and INR 873.35 per Equity Share
("NE" spectively, wh is higher than
The public shareholders of the Target Company are advised to independently evaluate the Open Offer
and take an informed decision about tendering the Equity Shares held by them in the Open Offer.
This statement of recommendation will be available on the website of www.glenmarklifesciences.com.

| $\begin{array}{l}\text { Disclosure of voting pattern } \\ \text { of the IDC }\end{array}$ | $\begin{array}{l}\text { The recommendations were unani } \\ \text { meeting held on } 10 \text { February, } 2024 .\end{array}$ |
| :--- | :--- |

Details of Independe
Advisors, if any.

## Any other ma highhighted

To the best of our knowledge and belief, after making proper enquiry, the information contained in or accompanying this statement is, in all material respect, true and correct and not misleading, whether by omission of any information or ot
information required to be disclosed by the Target Company under the SEBI (SAST) Regulations, 2011.

For
Glenmark Life Sciences Limited



| SHREE RAMA NEWSPRINT LIMITED <br> CIN-L21010GJ1991PLC019432 <br> Registered Office : Village : Barbodhan, Taluka : Olpad, Dist. Surat. Pin-395 005 (Gujarat) Tel: 02621-224203, 224204, 224205, 224207•Email: ramanewsprint@ramanewsprint.com |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023 |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
| $\begin{array}{\|l\|l} \mathrm{Sr} \\ \mathrm{No} . \end{array}$ | Particulars | $\begin{array}{\|c\|} \hline \text { Quarter } \\ \text { Ended } \\ \text { 31.12.2023 } \end{array}$ | $\begin{gathered} \text { Quarter } \\ \text { Ended } \\ 30.09 .2023 \\ \hline \end{gathered}$ | $\begin{array}{\|c\|} \hline \text { Quarter } \\ \text { Ended } \\ \text { 31.12.2022 } \\ \hline \end{array}$ | $\begin{array}{\|c\|} \hline \text { Nine Months } \\ \text { Ended } \\ 31.12 .2023 \\ \hline \end{array}$ | Nine Months <br> Ended <br> 31.12.2022 |  |
|  |  | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| Total Income from Operations |  | 1,370.61 | 945.78 | 1,335.84 | 3,486.73 | 3,350.17 | 4,834.04 |
| 2 | Net Profit / (Loss) for the period (before tax and exceptional items) | (687.90) | (979.27) | 148.78 | (2,570.84) | 179.31 | 192.04 |
| 3 | Net Profit / (Loss) for the period before tax (after exceptional items) | (687.90) | (979.27) | 148.78 | (2,570.84) | 179.31 | 192.04 |
| 4 | Net Profit / (Loss) for the period after tax (after Exceptional items) from continuing operation | (687.90) | (979.27) | 148.78 | (2,570.84) | 79.31 | 92.04 |
| Net Profit / (Loss) for the period after tax (after Exceptional items) from discontinued operation <br> Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)] |  | (320.85) | (272.26) | (829.39) | (751.01) | (1,941.65) | (12,010.59) |
|  |  | $(1,004.89)$ | (1,247.72) | (680.99) | (3,311.70) | (1,762.64) | (1,80. |
| 7 | Equity Share Capital | 14,752.20 | 14,752.20 | 14,752.20 | 14,752.20 | 14,752.20 | 14,752.20 |
| 9 | Other Equity |  |  |  |  |  | (704.29) |
|  | Earnings Per Share (of Rs 10/- each) from continuing operation (not annualised ) | (0.47) |  |  |  |  |  |
|  |  Basic \& Diluted (In Rs.) <br> 10 $\begin{array}{l}\text { Earnings Per Share (of Rs 10/- each) from discontinued operation } \\ \text { (not annualised ) }\end{array}$ <br>  Bace |  |  | 0.10 | (1.74) | 0.12 | 0.13 |
|  |  |  |  |  |  |  |  |  |  |
|  | Basic \& Diluted (In Rs.) <br> Earnings Per Share (of Rs $10 /$ - each) from continuing and discontinued operation (not annualised) Basic \& Diluted (In Rs.) | (0.22) | (0.18) | (0.56) | (0.51) | (1.32) | (8.14) |
| 11 |  |  |  |  |  |  |  |
|  |  | (0.68) | (0.85) | (0.46) | (2.25) | (1.19) | (8.01) |
| 1. The above unaudited financial results for the quarter and nine months ended December 31, 2023, were reviewed by Audit Committee and approved by the Board of Directors in their meetings held on February 10, 2024 <br> 2. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Results are available on the websites of the Stock Exchange(s) www.bseindia.com \& www.nseindia.com and on company's website www.ramanewsprint.com <br> 3. The Paper division has been identified as Discontinued operations and accordingly, its operations are presented in accordance with Ind AS 105 . |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Place: Ahmedabad Date: 10.02.2024 |  |  |  |  |  |  |  |  |  | For, Shree Rama Newsprint Limited ddharth Chowdhary Whole-Time Director (DIN: 01798350) |  |  |

